Ember LifeSciences, Inc., an award-winning provider of advanced pharmaceutical cold chain solutions, has entered into a capital and business alliance with Alfresa Corporation "Alfresa", a subsidiary of Alfresa Holdings Corporation. The Alfresa Group has the No. 1 domestic net sales in the pharmaceutical wholesale bus…
Excedr, Inc., a leading provider of full-service laboratory equipment leasing solutions for the life sciences and healthcare industries, announced the closing of $25 million in growth capital. The round includes a $17 million senior credit facility from BOK Financial and $8 million in equity from existing investors an…
Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, announced that it has entered into a strategic collaboration with China National Pharmaceutical Group Co., Ltd.. The two parties will establish the Sinop…
The Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency, and CuspAI, the frontier AI materials science company, announced a five-year, multi-programme partnership. The collaboration aims to accelerate the discovery and experimental validation of new materials across semi…
Care Career, a rapidly growing healthcare workforce technology organization, announced the acquisition of MAS Medical Staffing, one of the Northeast's leading healthcare workforce organizations. Financial terms of the transaction were not disclosed. The acquisition represents Care Career's seventh strategic acquisiti…
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, and BioLife Solutions, Inc. , a leading developer and supplier of cell processing tools and services for the cell and gene therapy (“CGT”) market, announced they have entered into a definitive agreement under which Repligen, …
AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy. Dave …
Bayer, a global life sciences company, and Henry Ford Health announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer’s global drug development expertise with Henry Ford Health’s comprehensive clinical research program and its deep connection to the communit…
Samsung Biologics announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG, a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs). With this transactio…
Servier, an independent international pharmaceutical group governed by a foundation, announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc, for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and comme…
Page 1 of 36